Breakthrough nanovaccine uses tumor cell membranes and immune-boosting polymers to enhance personalized cancer immunotherapy, ...

GV20 Therapeutics (GV20), a clinical-stage AI-powered biotherapeutics company, today announced that Dr. Kristopher Wentzel ...

Researchers design a nanovaccine that detects MRSA toxins, kills bacteria with heat, and captures antigens to train the ...

A decades-old TB vaccine turned cancer therapy may unlock new immunotherapies by reprogramming immune cell development in the ...

This study reveals the potential of engineered phage-IL-12 therapy in melanoma, enhancing immune response and tumor ...

Novel combination with efti has met the trial's primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting ...

ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Kevin Zarrabi discussing the molecular characterization of STEAP1 and STEAP2 in advanced prostate cancer. STEAP 1 and 2 ...

Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announces the appointments of Dr Cristina Csimma as an independent ...

Thetis cells got their name because they share traits with two different types of antigen-presenting cells: medullary thymic epithelial cells and dendritic cells—just as Thetis in Greek ...